article Open AccessTop 10% cited
Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
Clinical Cancer Research · 2009 · Vol. 15(3) · pp. 971–979
Qiang Gao✉(Cancer Institute (WIA))Xiaoying Wang(Cancer Institute (WIA))Shuang‐Jian Qiu(Shanghai Medical College of Fudan University)Ichiro Yamato(Nara Medical University)Masayuki Sho(Nara Medical University)Yoshiyuki Nakajima(Nara Medical University)Jian Zhou(Cancer Institute (WIA))Baizhou LiYongyong Shi(Shanghai Medical College of Fudan University)Yongsheng Xiao(Cancer Institute (WIA))Yang Xu(Cancer Institute (WIA))Jia Fan(Shanghai Medical College of Fudan University)
Abstract
Our data suggest for the first time that PD-L1 status may be a new predictor of recurrence for HCC patients and provide the rationale for developing a novel therapy of targeting the PD-L1/PD-1 pathway against this fatal malignancy.
Cancer Immunotherapy and BiomarkersHepatocellular Carcinoma Treatment and PrognosisImmunotherapy and Immune ResponsesGranzyme BHepatocellular carcinomaTissue microarrayFOXP3MedicineImmunohistochemistryCytotoxic T cellOncologyImmune systemTumor-infiltrating lymphocytes
MeSH terms
AdolescentAdultAgedAged, 80 and overFemaleCarcinoma, HepatocellularHumansLiver NeoplasmsMaleMiddle AgedPrognosisRecurrenceBiomarkers, TumorAntigens, CDDisease Progression
Funding
- National Natural Science Foundation of China
- Ministry of Education of the People's Republic of China
- Fudan University
Citations
812
FWCI
10.48
field-weighted impact
References
52
Percentile
99%
vs. same field & year
Citations per year
Cited by
Emerging Therapies for Hepatocellular Carcinoma (HCC)
Cancers · 2022 · 291 citations
Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion
Frontiers in Oncology · 2018 · 322 citations
T-cell exhaustion in the tumor microenvironment
Cell Death and Disease · 2015 · 1,120 citations
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
The Lancet Oncology · 2018 · 2,498 citations
Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy
Annals of Oncology · 2016 · 1,344 citations
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
New England Journal of Medicine · 2016 · 9,911 citations
References
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
Nature Medicine · 1999 · 2,463 citations
Global Cancer Statistics, 2002
CA A Cancer Journal for Clinicians · 2005 · 18,373 citations
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Nature Immunology · 2007 · 1,501 citations
Global cancer statistics
CA A Cancer Journal for Clinicians · 2011 · 55,006 citations
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Nature Immunology · 2001 · 2,931 citations
Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer
Clinical Cancer Research · 2005 · 789 citations
Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity
Cancer Research · 2005 · 998 citations
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
JNCI Journal of the National Cancer Institute · 2008 · 1,656 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.